Cargando…

Targeting the glycans of the HIV envelope as a therapeutic tool

Detalles Bibliográficos
Autor principal:	Balzarini, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236884/ http://dx.doi.org/10.1186/1742-4690-8-S2-O38

Ejemplares similares

118 The dense glycan shield on the HIV envelope: the Achilles heel of the virus?
por: Balzarini, Jan
Publicado: (2014)

Improving the immunogenicity of HIV-1 envelope trimer vaccines
por: Sanders, Rogier W
Publicado: (2011)

Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer
por: Mao, Youdong, et al.
Publicado: (2013)

S8.3c Cell wall glycans as targets for the development of new antifungals
por: Aimanianda, Vishukumar, et al.
Publicado: (2022)

Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes
por: Pollara, J, et al.
Publicado: (2012)

Several N-Glycans on the HIV Envelope Glycoprotein gp120 Preferentially Locate Near Disulphide Bridges and Are Required for Efficient Infectivity and Virus Transmission
por: Mathys, Leen, et al.
Publicado: (2015)

The transmembrane envelope protein of HIV-1 and other retroviruses modulate cytokine production and induce Treg cells
por: Behrendt, Rayk, et al.
Publicado: (2006)

HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
por: Kovacs, JM, et al.
Publicado: (2012)

Characterization of glycans of CD4+T cells in HAM/TSP
por: Kodama, Daisuke, et al.
Publicado: (2014)

Identification of a clade A HIV envelope immunogen from Protocol G that elicits neutralizing antibodies to tier 2 viruses
por: Hoffenberg, S, et al.
Publicado: (2012)

Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation
por: Kumar, R, et al.
Publicado: (2012)

HIV-1 RNA processing as therapeutic target: characterization of small molecule modulators of HIV-1 RNA processing and transport
por: Wong, Raymond, et al.
Publicado: (2013)

Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C
por: Fouda, G, et al.
Publicado: (2012)

Can ultrasound contrast agents increase the treatment envelope?
por: McDannold, Nathan, et al.
Publicado: (2015)

Conformational Heterogeneity of the HIV Envelope Glycan Shield
por: Yang, Mingjun, et al.
Publicado: (2017)

Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy
por: Balzarini, Jan
Publicado: (2007)

S8.3b How fungal cell wall glycans modulate the activation of platelets ?
por: Jawhara, Samir
Publicado: (2022)

The syncytin-A envelope gene of retroviral origin is essential for mouse placental development
por: Dupressoir, Anne, et al.
Publicado: (2009)

Contribution of captured retroviral envelope genes, the "synctins" to the formation of the mouse placenta
por: Dupressoir, Anne, et al.
Publicado: (2011)

Expanding the treatment envelope for brain therapy: simulation models and head phantoms
por: Eames, Matt, et al.
Publicado: (2015)

Engineering of a Lectibody Targeting High-Mannose-Type Glycans of the HIV Envelope
por: Hamorsky, Krystal Teasley, et al.
Publicado: (2019)

Tax as a therapeutic target in ATL
por: Dassouki, Zeina, et al.
Publicado: (2015)

Computerized screening tools for neurocognitive impairment in patients with HIV infection
por: Cercel, Ioana-Catrinel, et al.
Publicado: (2014)

Towards gene therapy against HIV-1: new therapeutic target in gag RNA accessible to ribozymes and RNA interference molecules
por: Gatignol, A, et al.
Publicado: (2014)

Angiogenesis and arthritis: a potential therapeutic target?
por: Grosjean, J, et al.
Publicado: (2004)

Interleukin-6 as a therapeutic target in locomotor disorders
por: Nishimoto, Norihiro, et al.
Publicado: (2012)

Telomerase: a breast cancer chemopreventive and therapeutic target
por: Shay, JW
Publicado: (2000)

OA021-04. HIV-1 gp41 envelope MPER mutation altered epitope conformation in lipid and increased sensitivity to 2F5 and 4E10 neutralizing antibodies
por: Shen, X, et al.
Publicado: (2009)

Next-generation LTR-specific Tre-recombinase targets a majority of HIV-1 isolates
por: Hauber, Joachim, et al.
Publicado: (2014)

The use of cryo electron microscopy to reveal the distribution and 3D structure of AIDS virus envelope spikes
por: Zhu, P, et al.
Publicado: (2006)

Cytomics of the tumour microenvironment: therapeutic targeting (keynote lecture)
por: Smith, Paul
Publicado: (2015)

MDR1 gene polymorphisms and HIV therapeutic response in South Indian population
por: Lingaiah, Shruthi, et al.
Publicado: (2014)

Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions
por: Seabright, Gemma E., et al.
Publicado: (2020)

3D culture system of muscle precursor cell to reveal mechanosensing defects in nuclear envelope related disorders
por: Coirault, Catherine
Publicado: (2015)

P403 Metagenomic sequencing as an effective diagnostic tool for Talaromycosis in HIV-negative patients: A retrospective study
por: Liang, Tianwei, et al.
Publicado: (2022)

Therapeutic targets for rheumatoid arthritis: lessons from animal models
por: Iwakura, Yoichiro, et al.
Publicado: (2012)

Epigenetic modifications of HIV proviral LTRs: potential targets for cure
por: Doerfler, W, et al.
Publicado: (2012)

A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART
por: Jackson, AG, et al.
Publicado: (2012)

Structural Rearrangements Maintain the Glycan Shield of an HIV-1 Envelope Trimer After the Loss of a Glycan
por: Ferreira, Roux-Cil, et al.
Publicado: (2018)

HIV infection destabilizes a targeted subset of the gamma/delta T cell repertoire
por: Hebbeler, Andrew M, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_a2bqos13ulfeg08eh8oo78hpdq